Want to see MHUAF full AI Analyst Report?
Top Page
Meihua International Medical Technologies Co Ltd
(OTC:MHUAF)
Select Model
Select Model
Rating:58Neutral
Price Target:
$7.00
▲(2.64% Upside)
Action:Reiterated
Date:08/06/26
The score is driven mainly by mixed financial performance: a strong, conservatively financed balance sheet is offset by a clear 2025 operating downshift and highly volatile cash generation. Technical indicators also weigh on the score due to bearish trend/momentum. These risks are partially balanced by an extremely low P/E valuation metric.
Positive Factors
Conservative balance sheet
Low leverage and a large equity base provide financial resilience, reduce refinancing pressure, and preserve capacity to fund operations or strategic initiatives despite weaker earnings.
Negative Factors
Sharp revenue contraction
The steep 2025 decline, following several years of modest decreases after the 2020–2021 peak, indicates weakening demand or competitiveness and reduces operating leverage across the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a large equity base provide financial resilience, reduce refinancing pressure, and preserve capacity to fund operations or strategic initiatives despite weaker earnings.
Read all positive factors
Meihua International Medical Technologies Co Ltd (MHUAF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.12M
Dividend YieldN/A
Average Volume (3M)187.00
Price to Earnings (P/E)0.5
Beta (1Y)0.75
Revenue Growth-36.24%
EPS Growth-61.74%
CountryUS
Employees486
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)15.09
Shares Outstanding857,914
10 Day Avg. Volume36
30 Day Avg. Volume187
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.01
P/FCF Ratio1.39
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Meihua International Medical Technologies Co Ltd Business Overview & Revenue Model
Company Description
Meihua International Medical Technologies Co., Ltd. is a Chinese company dedicated to the innovation, production, and distribution of a wide array of medical devices. Operating primarily within the People's Republic of China, its comprehensive pro...
How the Company Makes Money
The company primarily makes money by selling medical devices and medical consumables to healthcare providers and medical supply distributors. Key revenue is generated from (1) product sales of disposable medical supplies (recurring demand driven b...
Meihua International Medical Technologies Co Ltd Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
82
Very Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 61.79M | 96.91M | 97.10M | 103.35M | 104.04M |
| Gross Profit | 18.99M | 33.30M | 33.09M | 38.10M | 39.81M |
| EBITDA | 8.83M | 15.70M | 15.77M | 11.65M | 27.03M |
| Net Income | 6.78M | 10.84M | 11.63M | 6.24M | 20.95M |
Balance Sheet | |||||
| Total Assets | 207.18M | 186.24M | 171.92M | 163.58M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 15.15M | 15.96M | 16.93M | 26.74M | 8.15M |
| Total Debt | 8.99M | 7.95M | 7.33M | 6.81M | 5.18M |
| Total Liabilities | 18.25M | 27.26M | 25.08M | 24.90M | 29.09M |
| Stockholders Equity | 188.93M | 158.98M | 146.33M | 138.12M | 106.81M |
Cash Flow | |||||
| Free Cash Flow | 554.25K | 14.50M | -2.41M | -11.86M | -904.89K |
| Operating Cash Flow | 569.88K | 14.64M | 2.28M | -9.16M | -54.66K |
| Investing Cash Flow | -20.13M | -20.42M | -12.46M | -8.62M | -833.82K |
| Financing Cash Flow | 17.19M | 6.21M | 706.13K | 37.25M | 1.86M |
Meihua International Medical Technologies Co Ltd Risk Analysis
Meihua International Medical Technologies Co Ltd disclosed 80 risk factors in its most recent earnings report. Meihua International Medical Technologies Co Ltd reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Techniques employed by short sellers may drive down the market price of our Ordinary Shares. Q4, 2023
2.
Future sales of our Ordinary Shares, whether by us or our shareholders, could cause our share price to decline. Q4, 2023
3.
Raising additional capital and the sale of additional Ordinary Shares or other equity securities could result in dilution to our shareholders, while the incurrence of debt may impose restrictions on our operations. Q4, 2023
Meihua International Medical Technologies Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $6.12M | 0.46 | 3.83% | ― | -36.24% | -61.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $8.01M | -0.69 | -88.90% | ― | 72.50% | 58.34% | |
43 Neutral | $9.38M | -0.01 | -18.55% | ― | ― | ― | |
42 Neutral | $2.38M | -0.02 | -2135.52% | ― | ― | 99.51% |
* Healthcare Sector Average
MHUAF
Meihua International Medical Technologies Co Ltd
7.13
-30.67
-81.14%
GCTK
GlucoTrack
2.98
-68.12
-95.81%
LUCY
Innovative Eyewear, Inc.
0.93
-0.84
-47.51%
WOK
WORK Medical Technology Group LTD
2.10
-782,497.90
-100.00%
Meihua International Medical Technologies Co Ltd Corporate Events
Meihua International Medical Technologies Accelerates Pivot to Global Healthcare SaaS Platform
Jun 26, 2026
Meihua International Medical Technologies has formally outlined its strategic shift toward a SaaS-driven model, following the July 2025 launch of a trial software business that contributed about 2.6% of 2025 revenue. Through Meihua Future in New Y...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.